Natural control of HIV infection in young women in South Africa: HPTN 068

Mariya V. Sivay, PhD,
Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA,
410-614-6498, msivay1@jhmi.edu

Jessica M. Fogel, PhD,

Address correspondence and reprint requests to: Susan H. Eshleman, Address: 720 Rutland Avenue, Ross 646, Baltimore, Maryland 21205, Phone: 410-614-4734, Fax: 410-502-9244, seshlem@jhmi.edu.

Author roles: All authors contributed to manuscript preparation. Additional author roles are listed below.

Mariya V. Sivay: Performed HIV genotyping; analyzed data; drafted the manuscript
Jessica M. Fogel: Analyzed data; drafted the manuscript
Jing Wang: Data analyst for HPTN 068
Yinfeng Zhang: Analyzed antiretroviral drug data
Estelle Piwowar-Manning: HPTN LC QAQC Representative for HPTN 068
William Clarke: Responsible for antiretroviral drug testing
Autumn Breaud: Performed antiretroviral drug testing
Joel Blankson: Provided expertise on viremic control of HIV infection
Erica L. Hamilton: HPTN Leadership and Operations Center Representative for HPTN 068
Kathleen Kahn: Site investigator for HPTN 068
Amanda Selin: Research Associate for HPTN 068
F. Xavier Gomez-Olive: Site investigator for HPTN 068
Catherine MacPhail: Study investigator for HPTN 068
James P. Hughes: Statistician for HPTN 068
Audrey Pettifor: Protocol Chair for HPTN 068

Author biographies:

Mariya V. Sivay, PhD: Postdoctoral Fellow at Johns Hopkins Univ. School of Medicine
Jessica M. Fogel, PhD: Research Associate at Johns Hopkins Univ. School of Medicine
Jing Wang, MS, MA: Statistical Research Associate at Statistical Center for HIV/AIDS Research & Prevention (SCHARP)
Yinfeng Zhang, PhD: Postdoctoral Fellow at Johns Hopkins Univ. School of Medicine
Estelle Piwowar-Manning, BS, MT (ASCP): HIV Prevention Trials Network Laboratory Center Deputy Director
William Clarke, PhD: Associate Professor of Pathology at Johns Hopkins Univ. School of Medicine; Director of the Clinical Toxicology and Critical and Point-of-Care Testing Program at Johns Hopkins Hospital
Autumn Breaud, MS: Research Specialist at Johns Hopkins Univ. School of Medicine
Joel Blankson, MD, PhD: Associate Professor of Medicine at Johns Hopkins Univ. School of Medicine
Erica L. Hamilton, MPH: Clinical Research Manager at FHI 360
Kathleen Kahn, MD: Professor at School of Public Health, University of the Witwatersrand; Senior Scientist at MRC/Wits Rural Public Health and Health Transitions Research Unit (Agincourt)
Amanda Selin, MHS: Project Manager at Univ. of North Carolina at Chapel Hill
F. Xavier Gomez-Olive, MD, PhD: HIV and Chronic Care Theme Leader, Adult Health and Wellbeing Theme Leader at MRC/Wits Rural Public Health and Health Transitions Research Unit (Agincourt)
Catherine MacPhail, PhD: Senior Lecturer and Postgraduate Academic Program Director at School of Health and Society Univ. of Wollongong
James P. Hughes, PhD: HPTN SDMC Statistician at Univ. of Washington
Audrey Pettifor, PhD: Assistant Professor at Univ. of North Carolina at Chapel Hill
Susan H. Eshleman, MD, PhD: Professor of Pathology at Johns Hopkins Univ. School of Medicine; Director of the HIV Prevention Trials Network Laboratory Center

Note: Some of the work in this manuscript was presented as an abstract at the Conference on Retroviruses and Opportunistic Infections (CROI) in Boston, MA, USA (March, 2018)

Declaration of Interests and Source of Funding:

None of the authors has a conflict of interest or potential conflict of interest, with the following exceptions: Susan Eshleman has collaborated on research studies with investigators from Abbott Laboratories; Abbott Laboratories has provided reagents for collaborative research studies.
Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA, 410-614-6498, jfogel@jhmi.edu

Jing Wang, MS, MA,
Statistical Center for HIV/AIDS Research & Prevention (SCHARP), Seattle, WA, USA, 206-667-6357, jwang2@scharp.org

Yinfeng Zhang, PhD,
Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA, 410-614-6498, yzhan249@jhmi.edu

Estelle Piwowar-Manning, BS, MT (ASCP),
Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA, 410-614-6736, epiwowa@jhmi.edu

William Clarke, PhD,
Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA, 410-502-7692, wclarke@jhmi.edu

Autumn Breaud, MS,
Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA, 443-287-7662, abreaud1@jhmi.edu

Joel Blankson, MD, PhD,
Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA, 410-955-7757, jblanks@jhmi.edu

Erica L. Hamilton, MPH,
Science Facilitation Department, FHI 360, Durham, NC, USA, 919-544-7040, ehamilton@fhi360.org

Kathleen Kahn, MD,
MRC/Wits Rural Public Health and Health, Transitions Research Unit (Agincourt), School of Public Health, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa, 27-11-717-2617, kathleen.kahn@wits.ac.za

Amanda Selin, MHS,
University of North Carolina at Chapel Hill, Carolina Population Center, Chapel Hill, NC, USA, 919-360-5988, aselin@unc.edu

F. Xavier Gomez-Olive, MD, PhD,
MRC/Wits Rural Public Health and Health, Transitions Research Unit (Agincourt), School of Public Health, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa, 27-13-795-5076 ext 128, F.Gomez-OliveCasas@wits.ac.za

Catherine MacPhail, PhD,
School of Health and Society, University of Wollongong, Australia; MRC/Wits Rural Public Health and Health, Transitions Research Unit (Agincourt), School of Public Health, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa, 61-242-214-112, cmacphai@uow.edu.au

James P. Hughes, PhD,
Abstract

**Background:** Some individuals control HIV replication without antiretroviral (ARV) therapy.

**Objective:** To analyze viral suppression in young women in rural South Africa enrolled in a trial evaluating a behavioral intervention for HIV prevention.

**Methods:** Plasma samples were obtained from women ages 13–24 (81 infected at enrollment, 164 seroconverters). ARV testing was performed using an assay that detects 20 ARV drugs. Women were classified as viremic controllers if they were virally suppressed for ≥12 months with no ARV drug use.

**Results:** Samples from 216/245 (88.2%) women had no ARV drugs detected at their first HIV-positive visit. Thirty-four (15.7%) of the 216 women had a viral load <2,000 copies/mL. Fifteen of the 34 women were followed for ≥12 months; 12 were virally suppressed with no ARV drugs detected during follow-up. These women were classified as viremic controllers (overall: 12/216=5.6%). The median CD4 cell count at the first HIV-positive visit was higher among the 12 controllers than among the 204 women who were not using ARV drugs (759 vs. 549 cells/mm$^3$, $p=0.02$). Some women had a viral load <40 copies/mL at a single study visit, but none were classified as elite controllers (viral load <40 copies/mL for ≥12 months with no ARV drug use).

**Conclusions:** In this cohort, 5.6% of women who were not using ARV drugs had sustained viral suppression. This represents a minimum estimate of the frequency of viremic controllers in this cohort, since some women were not followed long enough to meet the criteria for classification.

**Keywords**

HIV; viremic controllers; natural control; young women; South Africa

Introduction

Some HIV-infected individuals are able to maintain low or undetectable levels of HIV RNA without antiretroviral therapy (ART).$^{1–3}$ These individuals often have low levels of viremia during acute infection, normal or slightly higher CD4 cell counts, normal levels of immune activity, and slower progression to AIDS.$^{4–6}$ The criteria used to classify these individuals as elite or viremic controllers vary, but are usually based on the degree of viral suppression and the duration of viremic control in the absence of ART.$^{7,8}$
Several factors have been associated with natural control of HIV infection. The ability to control viral replication to very low levels may reflect differences in viral genetics, host genetics, or innate, humoral, or adaptive immune responses. Most reports have not found an association between natural control of HIV infection and race, gender, age, or route of HIV acquisition. Most studies of HIV controllers rely on self-report or medical records to identify individuals who are not using antiretroviral (ARV) drugs. However, previous studies in both HIV-infected and HIV–uninfected cohorts have demonstrated that self-report of ARV drug use may be unreliable. We developed a high-throughput assay that detects 20 ARV drugs in five drug classes. This assay provides an objective method for assessing ARV drug use. In this report, we used the multi-drug assay to identify HIV controllers in a cohort of young women enrolled in a clinical trial (HIV Prevention Trials Network [HPTN] 068) in rural South Africa that evaluated a behavioral intervention for HIV prevention. HIV viral load is associated with HIV transmission risk and HIV treatment outcomes. Information on viremic control of HIV infection may help inform the design and interpretation of HIV treatment and prevention studies and may also be helpful for understanding the dynamics of the HIV epidemic in some populations.

Methods

Study cohort

Samples were obtained from women aged 13–24 who were enrolled in the HPTN 068 study (2011–2015). HPTN 068 evaluated whether a cash transfer conditional on school attendance reduced HIV incidence. Participants were followed until their expected school graduation date or study completion. A subset of participants had a single follow-up visit 1–2 years after their expected study exit (post-intervention follow-up study). At the time when HPTN 068 study was conducted, ART was recommended in the study region for individuals with CD4 cell counts ≤200 cells/mm³; earlier ART initiation was recommended for pregnant women and those with tuberculosis (CD4 cell count ≤50 cells/mm³).

Laboratory testing

HIV testing was performed at enrollment (all participants) and at annual follow-up visits for participants who were HIV uninfected at enrollment. CD4 cell count testing was performed at study sites for HIV-infected participants at their first HIV-positive visit and follow-up visits. Other laboratory testing described in this report was performed retrospectively at the HPTN Laboratory Center (Johns Hopkins University School of Medicine, Baltimore, MD, USA). HIV testing was performed to confirm results from site testing and to confirm HIV seroconversion events. HIV viral load testing was performed using the FDA-cleared RealTime HIV-1 Viral Load assay (Abbott Molecular, Abbott Park, IL; limit of quantification: 40 copies/mL). Rigorous procedures for sample collection, processing, storage, shipping, and testing were used throughout the HPTN 068 trial and in this study, to minimize any risk of sample degradation. ARV drug testing was performed using a qualitative multi-drug assay based on high-performance liquid chromatography coupled with high-resolution accurate mass mass spectrometry. HIV genotyping was performed using
the ViroSeq HIV-1 Genotyping System v2.8 (Abbott Molecular, Des Plaines, IL). HIV sequences generated with the ViroSeq system were used for HIV subtyping using the REGA HIV-1 Subtyping tool. Sequences were submitted to GenBank (Accession numbers: KY883695–KY883762, KY888784–KY888875, KY921717–KY921757).

Statistical analysis

HIV controllers were defined as having a viral load below a fixed cutoff (<40 copies/mL for elite controllers; <2,000 copies/mL for viremic controllers) at their first HIV-positive visit and one or more annual study visits (i.e., for at least 12 months), with no ARV drugs detected at those visits. Those who had a single viral load measurement ≥2,000 copies/mL during follow-up were included in this group. The viral load cutoffs used to define elite and viremic controllers in this report are used by International HIV Controller Consortium (www.hivcontrollers.org) and have been used in other reports. Statistical analysis was performed using the SAS software (SAS 9.4). Associations between viremic controllers and participant characteristics were examined using Wilcoxon rank sum tests.

Ethical considerations

Study participants and their parents/guardians provided written consent for participation in the HPTN 068 study. Written assent was obtained for participants younger than 18 years. The HPTN 068 study was approved by ethical review boards at participating institutions.

Results

The HPTN 068 cohort included 245 HIV-infected women; 81 were HIV-infected at enrollment and 164 acquired HIV infection during the study (seroconverters, Figure). ARV testing was performed using samples collected at the first HIV-positive visit; results were obtained for 242 of the 245 HIV-infected women. ARV drugs were detected in samples from 26 (10.7%) of the 242 women (10 infected at enrollment; 16 seroconverters, Figure). The 26 women with ARV drugs detected and the three women without ARV drug testing results were excluded from further analysis. Thirty-four (15.7%) of the remaining 216 women had a viral load <2,000 copies/mL at their first HIV-positive visit (12 infected at enrollment; 22 seroconverters); three of the 34 women had a viral load <40 copies/mL. The median viral load among the 34 women was 492 copies/mL (range: <40–1,479).

Fifteen (44.1%) of the 34 women who had an initial viral load <2,000 copies/mL were followed for at least 12 months (median follow-up period: 23 months, range: 13–51 months). Twelve of 15 participants had sustained viral suppression (viral load <2,000 copies/mL for at least 12 months; median follow-up: 20 months, range 13–42; one of the 12 women had a single elevated viral load result of 2,693 copies/mL during this period; Supplemental Figure). None of the 12 women had a sustained viral load <40 copies/mL (i.e., no elite controllers were identified in this study). ARV drugs were not detected in samples from any of the 12 women at any follow-up visit. These 12 women were classified as viremic controllers.

Age, viral load, and CD4 cell count were compared for the 12 viremic controllers and the other 204 women who had no ARV drugs detected at their first HIV-positive visit (control
group). The median age at the first HIV-positive visit was lower for the viremic controllers (17.5 years [range: 16–19] vs. 19 years [range: 13–24], p=0.04, Table). This most likely reflects selection bias, since the viremic controller group only included women with at least 12 months of follow-up; women with <12 months follow-up who were enrolled in HPTN 068 acquired HIV infection in the year before their last study visit. The median viral load at the first HIV-positive visit was lower for the viremic controllers than the control group, as expected (1,063 copies/mL [range: 61–1,479] vs. 17,911 copies/mL [range: <40–5,667,096]). The median CD4 cell count at the first HIV-positive visit was higher for the viremic controllers than the control group (759 cells/mm$^3$ [range: 448–1,817] vs. 549 cells/mm$^3$ [range: 13–1,440], p=0.02), and remained above 500 cells/mm$^3$ in seven of the 12 viremic controllers throughout the follow-up period (Supplemental Figure). There was no significant difference between the median CD4 cell count during the follow-up period among viremic controllers and the control group (542 cells/mm$^3$ vs. 538 cells/mm$^3$, respectively, p=0.42).

HIV genotyping was performed for 212 (92.3%) of the 245 HIV-positive women; 33 samples were not tested (viral load <400 copies/mL or no sample available for testing). Results were obtained for 201 (96.7%) of the 212 samples (11 samples failed testing). HIV genotyping results from the full HPTN 068 cohort are presented in a separate report.$^{25}$ HIV drug resistance results were obtained for five viremic controllers; (Y181C) was detected in only one of these cases. HIV subtyping was performed previously using $pol$ region sequences obtained from HIV genotyping. Two-hundred women had subtype C infection, including five of 12 viremic controllers; one woman had subtype A infection; the other seven viremic controllers did not have genotyping results (most due to low viral load).$^{26}$

**Discussion**

This report analyzed viral suppression in young women in rural South Africa. In this cohort, 216 (88.2%) of the 245 HIV-infected women were not taking ARV drugs at their first HIV-positive visit (enrollment or seroconversion). Some women had a viral load <40 copies/mL at a single study visit, but none met the criteria for elite controllers. Twelve (5.6%) of the 216 women had sustained viral suppression in the absence of ARV drug use and were classified as viremic controllers. This provides a minimum estimate of the frequency of viremic controllers in this cohort, because more than half of the 34 women who had an initial low viral load value and were not taking ARV drugs were not classified as viremic controllers because they were followed for <12 months. Based on results obtained for the women with ≥12 months follow-up, we estimate that the true frequency of viremic controllers in this cohort is 12.6% (34 women with initial viral suppression) × 80% sustained viral suppression] × 100% / 216 women with no ARV drugs detected). A previous study from South Africa reported a high prevalence (17.2%) of individuals who had viral loads <50 copies/mL in the absence of ART.$^{27}$ In other studies, the portion of individuals with natural control of HIV infection ranged from <1% to 7.7%.$^{2,3,8,11–13,22,28,29}$ These studies used different criteria to define HIV controllers. Two of these studies used the same viral load cutoff to define viremic controllers that was used in this report (2,000 copies/mL); those studies reported a prevalence of viremic controllers of 2.7%$^{22}$ and 3.34%.$^{2}$ ARV drug use was identified in some studies based on self-report or medical records;$^{11–13}$ some studies did not indicate how ARV drug use was assessed.$^{2,3,8,28,29}$ Our previous studies of men who
have sex with men, heterosexual couples, and women at high risk of HIV infection, demonstrate that some individuals may not disclose ARV drug use. Therefore, the frequency of HIV controllers may be lower than reported in studies that rely on self-report to assess ARV drug use.

Higher CD4 cell counts have been observed in HIV controllers in other studies. In this report, among women who were not taking ARV drugs, the median CD4 cell count was significantly higher among the viremic controllers compared to women with higher viral loads. However, we did not observe a significant difference in CD4 cell counts between these groups over time. Previous studies have showed an association of natural control of HIV infection with specific HLA class I alleles. However, the frequency of these alleles in HIV controllers varies from 15% to 86% in different populations, and some of the putatively “protective” HLA class I alleles were also identified in HIV progressors who were not virally suppressed. Therefore, it seems unlikely that HLA class I genotype alone leads to natural control of infection. Viral (HIV) genetics may also play a role in natural control of HIV infection.

Some HIV drug resistance mutations that have been associated with lower viral fitness (e.g., M184I/V) have been identified in some HIV controllers. In other cases, HIV controllers were infected with high-fitness viruses, that did not have mutations considered to be protective genetic factors. M184I/V was not detected in this study in the five viremic controllers who had HIV genotyping results. One viremic controller had HIV with the Y181C mutation; this mutation has a minimal impact on HIV replication capacity and has not been associated with lower viral load levels. Because drug resistance data were only obtained for five viremic controllers in the HPTN 068 study, we were not able evaluate whether drug resistance played a role in viremic control in this cohort. The HPTN 068 study did not obtain consent to perform host genetic testing, and phenotypic studies of HIV replication capacity could not be performed in this study because insufficient plasma was available for analysis.

Most prior reports have found no association of viremic control with gender, age, or race, though these associations have been reported in some studies. In our study, there was no age difference between women who had viral loads <2,000 copies/mL vs. >2,000 copies/mL at their first HIV-positive visit. Our finding that the median age of viremic controllers was lower than other women (p=0.04) most likely reflects the requirement for a 12-month follow-up for classification of viremic control. Women with longer follow-up after their first HIV-positive visit were more likely to have enrolled in the HPTN 068 study during an earlier school grade, when they were younger.

Previous studies found an association of disease progression with HIV subtype. For example, HIV subtype D infection has been associated with faster CD4 cell decline, frequent virologic rebound during ART, and higher rate of mortality compared to subtypes A, B and C. In one cohort, slower disease progression was observed in women with HIV subtype C infection compared to those with subtype A and D infection. HIV subtype was determined for the majority (82%) of the HIV-infected women in HPTN 068; all but one had subtype C infection, including all of the viremic controllers who had genotyping results.
One potential limitation of this report is that it included both women who were infected at study entry and those who acquired HIV infection during the study. Several factors make it less likely that were significant differences between the two study groups that might impact viremic control. HIV seroconverters were identified at annual study visits; therefore, these women were infected in the year prior to the seroconversion visit. Because the study enrolled women as young as 13 years of age, some women who were HIV infected at study entry were also likely to have been recently infected. The enrollment criteria for HPTN 068 were also not likely to have impacted enrollment of viremic controllers vs. non-controllers. There was no incentive for enrollment of HIV-uninfected women, and no cap or other disincentive for enrollment of those with known HIV infection or a history of ARV drug exposure. Overall, only 2% of young women and 5% of parent/guardians refused participation in the trial, and the baseline prevalence of HIV infection in HPTN 068 was 3.2%, which is similar to the prevalence of HIV in another study performed in population of school students in rural South Africa in the same age category (3.8%).

In conclusion, in this cohort of young women from rural South Africa, we identified a high portion of women who were virally suppressed in the absence of ARV drug use (N=34, 15.7%). Approximately one-third of these women had sustained viral suppression with no ARV drug use. The actual frequency of viremic controllers in this cohort may have been higher, since HIV infection in some women could not be fully characterized due to limited study follow-up. Based on results from women who were followed for at least one year, the prevalence of viremic controllers in this cohort was 12.6%. The relatively high frequency of viremic controllers in this population suggests that ARV drug testing may be useful in addition to HIV viral load testing for evaluating treatment outcomes in future studies, to distinguish between those with natural vs. ARV-induced viral suppression. This information may also be useful for studies of HIV transmission and dynamics among young women in similar settings, since viremic controllers are less likely to transmit HIV to others.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgements

The authors thank the HPTN 068 study participants and study team for providing samples and data for this study. The authors also thank the laboratory staff at the study sites and the HPTN Laboratory Center for their assistance with sample management and laboratory testing.

This work was supported by (1) UM1-AI068613 (Eshleman), UM1-AI068619 (Cohen/El-Sadr), and UM1-AI068617 (Donnell), from the National Institute of Allergy and Infectious Diseases, the National Institute of Mental Health and the National Institute on Drug Abuse of the National Institutes of Health; (2) R01-AI095068 (Eshleman); (3) R01-MH087118 (Pettifor); and (4) the Carolina Population Center and its NIH Center grant, P2C-HD050924.

References


Figure. Study cohort and identification of viremic controllers in the HPTN 068 cohort.
The figure shows the number of HPTN 068 participants who were HIV-infected at study enrollment and the number of women who acquired HIV infection during study follow-up (F/U). For each group, the figure shows the number of those participants who had no antiretroviral (ARV) drugs detected at their first HIV-positive visit (enrollment or seroconversion), the number of participants with viral load levels <2,000 copies/mL at their first HIV-positive visit, the number of participants with at least 12 months of follow-up, and the number identified as viremic controllers. Loss of virologic control was defined as having two or more HIV RNA measurements >2,000 copies/mL during study follow-up.
Abbreviations: mo.: month; F/U: follow-up.
### Table.

Characteristics of HIV-infected participants who had no ARV drugs detected at their first HIV-positive visit.

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Viremic controllers&lt;sup&gt;a&lt;/sup&gt; N=12</th>
<th>Other women N=204</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>First HIV-positive visit</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Median (range) viral load, copies/mL</td>
<td>1,063 (61–1,479)</td>
<td>17,911 (40–5,667,096)</td>
<td>NA&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
<tr>
<td>Median (range) age, years</td>
<td>17.5 (16–19)</td>
<td>19 (13–24)</td>
<td>0.04</td>
</tr>
<tr>
<td>Median (range) CD4 cell count, cells/mm&lt;sup&gt;3&lt;/sup&gt;</td>
<td>759 (448–1817)</td>
<td>549 (13–1440)</td>
<td>0.02</td>
</tr>
<tr>
<td><strong>During follow-up</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Median (range) CD4 cell count, cells/mm&lt;sup&gt;3&lt;/sup&gt;</td>
<td>542 (394–1130)</td>
<td>538 (77–1404)</td>
<td>0.42</td>
</tr>
</tbody>
</table>

<sup>a</sup> Participants who had a HIV viral load <2,000 copies/mL at their first HIV-positive visit with sustained viral suppression for at least 12 months (see Methods).

<sup>b</sup> A p value is not reported for this comparison, since viral load was used to identify viremic controllers (NA: not applicable).